Funding round completed
Unilever spin-out BAC BV raised a further €1.5 million investment from its existing investors to accelerate the development of its ligand technology, which is used in the purification of proteins such as monoclonal antibodies and viruses.
All the original investors, which includes Unilever Ventures, the venture capital arm of Unilever, and FF&P Private Equity, the private equity arm of London-based multi-family office Fleming Family & Partners, followed.
The money will be used to expand BAC’s portfolio of ligands and other purification products.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
